AlphAIAlphAI — Financial news for AI agents
stocktitan.netNOV 32 min read$IBO

Shareholders are set to vote Nov. 13 on a proposed combination. The SEC declared the deal paperwork effective.

DSS, Inc. (NYSE American:DSS) and Impact Biomedical Inc. (NYSE American:IBO) announced the SEC declared effective the registration statement for their business combination with Zoar Limited. The deal, pending shareholder approval and other conditions, aims to create a pharmaceutical company focused on active pharmaceutical ingredients. Impact's stockholders will vote on November 13, 2026.

Original reporting
stocktitan.net
Published Nov 3, 2026, 4:33 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 4:34 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMergers & acquisitions
Primary signal
$IBO
Neutral
high confidence
Mentioned
$IBO · $DSS
Relevance
7/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$IBONeutralMed
01

Why it matters

Approval would create a new specialty pharmaceutical entity; rejection would likely unwind the deal and depress both Impact and DSS shares.

02

Market read

The filing is a primary M&A disclosure that could move the involved stocks around the upcoming vote.

03

What to watch

Potential antitrust review and the ability of Zoar Labs to integrate Impact’s assets.

Relevance 7/10Novelty 7/10Timing: pre‑vote on Nov 13

Background

The SEC’s effectiveness filing clears a regulatory hurdle for the Impact‑Zoar‑PubCo business combination, setting the stage for a shareholder vote.

Company-level read

Ticker impact

$IBONeutralHigh confidence
Context

Impact Biomedical announced the SEC declared the Form F‑4 effective, moving the merger toward a shareholder vote on Nov 13.

Expected impact

potential pressure if vote fails; likely modest rally if approved

Evidence & confidence

Shareholder approval is a binary catalyst; market will price in the outcome quickly.

$DSSNeutralMedium confidence
Context

DSS, as majority shareholder of Impact, is a key participant in the announced business combination.

Expected impact

limited movement unless the vote outcome is unexpected

Evidence & confidence

DSS is a holding company; its price reacts mainly to the merger’s success or failure.

Market effects

Sector

Consolidation in specialty pharma/APIs could affect peers in the sector.

Regional

Limited to U.S. small‑cap biotech and holding‑company space.

Global

Minor; primarily impacts the involved companies.

Counterpoint

What could challenge this read

If the merger faces regulatory or integration hurdles, the vote could be a red flag and the stocks may decline.

Key entities

  • company
    Impact Biomedical Inc.

    Target company in the merger.

  • company
    DSS, Inc.

    Majority shareholder of Impact and participant in the deal.

  • company
    Zoar Limited

    Partner in the proposed combination.

Read at source← All news

StorySEC declares Form F‑4 effective, Impact shareholders to vote on Zoar merger Nov 13

Also covered by

2 outlets

Related articles

NOV 3
$DSSMed

DSS, Inc. Announces SEC Declaration of Effectiveness of Form F-4 Registration Statement, Marking Major Milestone Toward Closing of Proposed Business Combination

DSS, Inc. (DSS) announced the SEC declared effective the Form F-4 registration statement for its business combination with Impact Biomedical (IBO) and Zoar Limited. The combined company, Zoar Limited, is expected to trade on NYSE American under the ticker 'ZOAR,' pending approval. Impact stockholders will vote on the merger on November 13, 2026. The transaction remains subject to regulatory and shareholder approvals.

finanznachrichten.de2 min
NOV 3
$IBOMed

Impact Biomedical, Inc.: Impact Biomedical Inc. and Zoar Limited Announce SEC Declaration of Effectiveness of Form F-4 Registration Statement, Marking Major Milestone Toward Closing of Proposed Business Combination

Impact Biomedical (IBO) and Zoar Limited announced the SEC's approval of their Form F-4 registration statement for a business combination. The deal, pending shareholder and NYSE American approval, will result in a combined company operating as Zoar Limited (ZOAR). A special meeting for Impact stockholders is scheduled for November 13, 2026, to vote on the proposal.

finanznachrichten.de2 min
SEP 16
$IBOMed

Impact BioMedical, Inc.: Impact Biomedical Inc Announces Filing of Form F-4 Registration Statement in Connection with Proposed Merger with Zoar Ltd. (f/k/a Dr. Ashley's Limited)

Impact Biomedical Inc. (IBO) filed a Form F-4 registration statement with the SEC for its proposed merger with Zoar Ltd. The merger, subject to regulatory and shareholder approvals, aims to create a pharmaceutical company focused on active pharmaceutical ingredients. The completion depends on SEC approval, shareholder votes, and NYSE American listing.

finanznachrichten.de2 min
JUN 9
$DSSMed

DSS, Inc. Withdraws Registration Statement

DSS, Inc. (NYSE American: DSS) said it has withdrawn its previously filed Form S-1 registration statement with the SEC. The company attributed the decision to a review of current market conditions and deal terms, concluding the offering would not reflect its view of shareholder value. DSS said it will keep evaluating financing options and noted no change in business outlook.

itnewsonline.com3 min